| Literature DB >> 34886051 |
Beata Lindholm1,2, Erika Franzén3,4, Wojciech Duzynski2, Per Odin2,5, Peter Hagell5,6.
Abstract
People with Parkinson's disease (PwPD) have an increased risk for falls and near falls. They have particular difficulties with maintaining balance against an external perturbation, and several retropulsion tests exist. The Unified PD Rating Scale item 30 (UPDRS30) is the most common, involving an expected shoulder pull. Others recommend using an unexpected shoulder pull, e.g., the Nutt Retropulsion Test (NRT). We aimed to evaluate the clinical usefulness of these tests for detecting future fallers. By using two different golden standards related to self-reported prospective falls and near falls over 6 months following two different time points with 3.5 years between, we estimated sensitivity/specificity, Youden index, predictive values, and likelihood ratios for each test. The different time points yielded a different prevalence of falls and near falls, as well as different predictive values. When comparing the performance of the NRT and UPDRS30 for detecting future fallers, we found that the NRT consistently performed better than UPDRS30. However, neither test exhibited optimal performance in terms of predictive values and associated likelihood ratios. Our findings speak against using either of these tests as a single assessment for this purpose and support previous recommendations of using a multifactorial approach when targeting balance problems in PwPD.Entities:
Keywords: Parkinson’s disease; falls; near falls; postural stability; prediction; predictive value; pull test; retropulsion; sensitivity; specificity
Mesh:
Year: 2021 PMID: 34886051 PMCID: PMC8656501 DOI: 10.3390/ijerph182312325
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Sample characteristics.
| Time 1 | Time 2 | |
|---|---|---|
| Age (years), mean (SD; min–max) | 68 (9.6; 35–80) | 69 (8.9; 46–84) |
| Female gender, n (%) | 67 (46) | 32 (55) |
| PD duration (years), mean (SD; min–max) | 4.0 (3.9; 0.1–17.0) | 7.0 (3.7; 3.6–20) |
| PD severity (HY), median (q1–q3; min–max) | 2 (2–3; 1–4) | 2 (2–3; 1–4) |
| Daily total levodopa equivalent (LDE) dose (mg), median (q1–q3; min–max) | 400 (300−600; 0–1477) | 500 (400–675; 150–1580) |
| Self-rated motor status at the time of clinical examination | ||
| Motor symptoms (UPDRS part III), median (q1–q3; min–max) | 12 (8–18; 1–46) | 13.5 (9–20; 1–40) |
| Cognition (MMSE), median (q1–q3; min–max) | 28 (26–29; 19–30) | 28 (27–29; 20–30) |
| Retropulsion (NRT), median (q1–q3; min–max) | 0 (0–1; 0–2) | 0 (0–1; 0–3) |
| Retropulsion (UPDRS30), median (q1–q3; min–max) | 0 (0–1; 0–2) | 0 (0–1; 0–3) |
HY, Hoehn and Yahr; MMSE, Mini-Mental State Examination; NRT, Nutt Retropulsion Test; PD, Parkinson’s disease; UPDRS, Unified Parkinson’s Disease; Rating Scale; UPDRS part III, motor score of the Unified Parkinson’s Disease Rating Scale; UPDRS30, item 30 of UPDRS.
Sensitivity, specificity, Youden index, predictive values, and likelihood ratios for different cut-off scores of the NRT and UPDRS30 with prospective falls and near falls as golden standards at Time 1 (n = 146).
| Cut-Off Score | Sens (95% CI) | Spec (95% CI) | YI (95% CI) | PPV (95% CI) | NPV (95% CI) | LR+ (95% CI) | LR− (95% CI) | ||
|---|---|---|---|---|---|---|---|---|---|
| Golden standard: falls (prevalence, 32%) | |||||||||
| NRT | <0.001 | 1 | 0.47 (0.33–0.61) | 0.85 (0.77–0.10) | 0.32 (0.16–0.48) | 0.60 (0.46–0.72) | 0.77 (0.72–0.82) | 3.09 (1.77–5.39) | 0.63 (0.47–0.83) |
| 2 | 0.34 (0.22–0.48) | 0.96 (0.90–0.98) | 0.30 (0.16–0.44) | 0.80 (0.60–0.91) | 0.75 (0.71–0.91) | 8.43 (2.98–23.82) | 0.69 (0.56–0.82) | ||
| UPDRS i 30 | 0.010 | 1 | 0.51 (0.37–0.65) | 0.70 (0.60–0.78) | 0.21 (0.04–0.38) | 0.44 (0.35–0.55) | 0.75 (0.69–0.83) | 1.69 (1.12–2.54) | 0.70 (0.51–0.97) |
| 2 | 0.19 (0.10–0.34) | 0.95 (0.89–0.98) | 0.14 (0.02–0.26) | 0.64 (0.40–0.83) | 0.71 (0.68–0.74) | 3.79 (1.34–10.69) | 0.85 (0.74–0.99) | ||
| Golden standard: falls and/or near falls (prevalence, 46%) | |||||||||
| NRT | 0.001 | 1 | 0.40 (0.29–0.52) | 0.87 (0.78–0.93) | 0.28 (0.14–0.41) | 0.73 (0.59–0.84) | 0.63 (0.58–0.68) | 3.18 (1.66–5.49) | 0.68 (0.55–0.85) |
| 2 | 0.25 (0.17–0.37) | 0.93 (0.89–0.99) | 0.22 (0.10–0.33) | 0.85 (0.65–0.95) | 0.60 (0.57–0.64) | 6.68 (2.05–21.82) | 0.78 (0.67–0.90) | ||
| UPDRS30 | 0.005 | 1 | 0.49 (0.38–0.61) | 0.73 (0.63–0.82) | 0.23 (0.07–0.38) | 0.61 (0.50–0.71) | 0.63 (0.57–0.69) | 1.85 (1.19–2.88) | 0.69 (0.53–0.91) |
| 2 | 0.15 (0.08–0.25) | 0.95(0.88–0.98) | 0.10 (0.00–0.20) | 0.71 (0.46–0.88) | 0.57 (0.54–0.60) | 2.95 (0.97–8.97) | 0.90 (0.80–1.00) | ||
1 those with score 3 were not included at Time 1; 2 those with scores 3 or 4 were not included at Time 1; YI, Youden index; LR+/−, positive/negative likelihood ratio; NPV, negative predictive value; NRT, Nutt Retropulsion Test; PPV, positive predictive value; ROC, receiver operating characteristics; Sens, sensitivity; Spec, specificity; UPDRS30, item 30 of the Unified Parkinson’s Disease Rating Scale.
Sensitivity, specificity, Youden index, predictive values, and likelihood ratios for different cut-off scores of the NRT and UPDRS30 with prospective falls and near falls as golden standards at Time 2 (n = 58).
| Cut–Off Score | Sens (95% CI) | Spec (95% CI) | YI (95% CI) | PPV (95% CI) | NPV (95% CI) | LR+ (95% CI) | LR− (95% CI) | ||
|---|---|---|---|---|---|---|---|---|---|
| Golden standard: falls (prevalence, 45%) | |||||||||
| NRT | 0.034 | 1 | 0.48 (0.30–0.67) | 0.78 (0.61–0.89) | 0.26 (0.02–0.50) | 0.63 (0.46–0.79) | 0.66 (0.56–0.75) | 2.19 (1.01–4.75) | 0.67 (0.44–1.01) |
| 2 | 0.23 (0.11–0.42) | 0.91 (0.77–0.98) | 0.14 (−0.05–0.33) | 0.68 (0.28–0.95) | 0.59 (0.53–0.65) | 2.46 (0.68–8.90) | 0.85 (0.67–1.08) | ||
| 3 | 0.08 (0.02–0.24) | 1.00 (0.89–1.00) | 0.08 (−0.03–0.18) | 1.00 (0.13–1.00) | 0.57 (0.52–0.62) | NA (0.18–NA) | 0.92 (0.83–1.03) | ||
| UPDRS30 | 0.079 | NA | |||||||
| Golden standard: falls and/or near falls (prevalence, 52%) | |||||||||
| NRT | 0.043 | 1 | 0.45 (0.28–0.63) | 0.79 (0.61–0.90) | 0.23 (0.00–0.47) | 0.68 (0.50–0.83) | 0.58 (0.48–0.67) | 2.09 (0.92–4.73) | 0.70 (0.48–4.73) |
| 2 | 0.20 (0.10–0.37) | 0.89 (0.73–0.96) | 0.09 (−0.09–0.28) | 0.66 (0.27–0.91) | 0.51 (0.45–0.57) | 1.87 (0.52–6.76) | 0.90 (0.72–1.12) | ||
| 3 | 0.07 (0.02–0.21) | 1.00 (0.88–1.00) | 0.07 (−0.02–0.16) | 1.00 (0.15–1.00) | 0.50 (0.45–0.56) | NA (0.16–NA) | 0.93 (0.85–1.03) | ||
| UPDRS30 | 0.231 | NA | |||||||
YI, Youden index; LR+/−, positive/negative likelihood ratio; NA, not applicable; NPV, negative predictive value; NRT, Nutt Retropulsion Test; PPV, positive predictive value; ROC, receiver operating characteristics; Sens, sensitivity; Spec, specificity; UPDRS30, item 30 of the Unified Parkinson’s Disease Rating Scale.